0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > ErbB3

ErbB3

Brief Information

Name:Receptor tyrosine-protein kinase erbB-3
Target Synonym:EC:2.7.10.1,FERLK,EC 2.7.10,Proto-oncogene-like protein c-ErbB-3,HER3,ERBB3,Erb-B2 Receptor Tyrosine Kinase 3,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3,Tyrosine Kinase-Type Cell Surface Receptor HER3,Human Epidermal Growth Factor Receptor 3,Lethal Congenital Contracture Syndrome 2,Receptor Tyrosine-Protein Kinase ErbB-3,EC 2.7.10.1,P180-ErbB3,P45-SErbB3,P85-SErbB3,MDA-BF-1,C-ErbB-3,C-ErbB3,ErbB3-S,ErbB-3,LCCS2,Receptor, ErbB-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP149-Cell-based assay
 ErbB3 FACS

Expression analysis of human ErbB3 on HEK293/Human ErbB3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ErbB3 Stable Cell Line or negative control cell using PE-labeled anti-human ErbB3 antibody.

ER3-H82E6-ELISA
 ErbB3 ELISA

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).

ER3-M52H5-MALS-HPLC
ErbB3 MALS images

The purity of Mouse ErbB3, His Tag (Cat. No. ER3-M52H5) is more than 85% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.

Synonym Name

ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3

Background

ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Osimertinib Mesylate AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 Approved Astrazeneca Plc 泰瑞沙, Tagrisso United States Carcinoma, Non-Small-Cell Lung Astrazeneca Pharmaceutical Co Ltd 2015-11-13 Uterine Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Adenocarcinoma of Lung; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Esophageal Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Hematologic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Neoplasms; Glioblastoma; Colonic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Izalontamab SI-B001; SI-1X6.4 Phase 3 Clinical Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
Izalontamab brengitecan BL-B01D1 Phase 3 Clinical SystImmune Nasopharyngeal Carcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Solid tumours; Digestive System Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms, Fibroepithelial Details
Nezutatug HMBD-001 Phase 2 Clinical Hummingbird Bioscience Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Uterine Cervical Neoplasms Details
Sapitinib AZD-8931 Phase 2 Clinical Astrazeneca Plc Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Seribantumab MM-121; SAR-256212; 1N3L70MDFX (UNII code) Phase 2 Clinical Merrimack Pharmaceuticals Inc Prostatic Neoplasms; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lung Neoplasms; Gallbladder Neoplasms; Uterine Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Sarcoma; Cholangiocarcinoma; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Kidney Neoplasms; Solid tumours Details
Tesevatinib XL-647; KD-020; KD-019; EXEL-7647 Phase 2 Clinical Exelixis Inc Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Zenocutuzumab MCLA-128 Phase 2 Clinical Merus Nv Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
89Zr-Patritumab deruxtecan Phase 2 Clinical Daiichi Sankyo Co Ltd, The Netherlands Cancer Institute, Daiichi Sankyo Inc Carcinoma, Non-Small-Cell Lung Details
IBI-133 IBI133; IBI-133 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
DB-1310 DB-1310 Phase 2 Clinical Solid tumours; Neoplasm Metastasis Details
SIBP-03 SIBP-03 Phase 2 Clinical Shanghai Institute Of Biological Products Co Ltd Squamous Cell Carcinoma of Head and Neck; Neoplasms Details
SHR-A2009 SHR-A2009 Phase 2 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd Solid tumours; Breast Neoplasms Details
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) JK07; SAL-007 Phase 2 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Heart Failure Details
Elgemtumab NOV-6; LJM-716 Phase 1 Clinical Novartis Pharma Ag, Morphosys Ag Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma Details
MP-0274 DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 Phase 1 Clinical Molecular Partners Ag Neoplasms Details
AV-203 AV-203; CAN-017 Phase 1 Clinical Aveo Solid tumours; Neoplasms Details
Barecetamab ISU-104 Phase 1 Clinical Isu Abxis Co Ltd Solid tumours Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
SYS-6023 SYS-6023; SYS6023 Phase 1 Clinical Jushi Biopharmaceutical Co Ltd Solid tumours Details
AMT-562 AMT-562 Phase 1 Clinical Multitude Therapeutics Inc Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SIBP-A13 SIBP-A13 Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Head and Neck Neoplasms; Solid tumours; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase 1 Clinical Zensun (Shanghai) Sci&Tech Co Ltd Neoplasms Details
Recombinat humanized HER3-targeting antibody Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop

Laisser un message